Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B001 in Aquaporin-4 Antibody Positive NMOSD
NCT06413654Phase 3Recruiting
- Sponsor
- Shanghai Cross-linked Pharmaceutical Research and Development
- Start
- Jul 2024
- Primary completion
- Oct 2027
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Neuromyelitis Optica Spectrum Disorder (NMOSD) comparing B001 injection with Placebo (2 arms). Primary endpoint: Time to first Neuromyelitis Optica Spectrum Disorder Attack at 48 weeks. Started Jul 2024; status: recruiting.
02
Drugs
B001
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT06413654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06413654.